The biotech industry is expanding due to an aging population, increased investments in research and development, growing healthcare applications, development of innovative drugs and therapies, increasing need for personalized medicines and effective treatments of rare and prevalent diseases, and collaborations.
Given the industry’s solid growth prospects, investors could consider buying fundamentally strong biotech stocks BioMarin Pharmaceutical Inc. (BMRN), Illumina, Inc. (ILMN), and Harmony Biosciences Holdings, Inc. (HRMY). These stocks are B (Buy)-rated in our proprietary POWR Ratings system.
